NRIX Nurix Therapeutics Inc.

35.61
+2.19  (+7%)
Previous Close 33.42
Open 33.54
52 Week Low 15.21
52 Week High 52.38
Market Cap $1,383,642,183
Shares 38,855,439
Float 25,491,435
Enterprise Value $1,173,593,067
Volume 392,338
Av. Daily Volume 340,999
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
DeTIL-0255
Cellular therapy
Phase 1
Phase 1
Phase 1 trial to be initiated 2H 2021.
NX-5948
B-cell malignancies / graft-versus-host disease
Phase 1
Phase 1
Phase 1 trial to be initiated 2H 2021.
NX-1607
Immuno-oncology indications
Phase 1
Phase 1
Phase 1 trial to be initiated 2H 2021.
NX-2127
B-cell malignancies
Phase 1
Phase 1
Phase 1 trial planned for 1Q 2021.

Latest News

  1. First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refractory B-cell malignancies

    Three additional wholly owned programs expected to enter clinical trials in 2021

    Expanded Sanofi collaboration resulting in option exercise payment of $22 million

    Year-end cash and investments totaling $372 million

    SAN FRANCISCO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the fourth quarter and fiscal year ended November 30, 2020 and provided a corporate update.

    "We begin 2021 with a positive notification from the FDA that our first Phase 1 clinical trial of NX-2127 may…

    First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refractory B-cell malignancies

    Three additional wholly owned programs expected to enter clinical trials in 2021

    Expanded Sanofi collaboration resulting in option exercise payment of $22 million

    Year-end cash and investments totaling $372 million

    SAN FRANCISCO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the fourth quarter and fiscal year ended November 30, 2020 and provided a corporate update.

    "We begin 2021 with a positive notification from the FDA that our first Phase 1 clinical trial of NX-2127 may proceed in patients with B cell malignancies, including chronic lymphocytic leukemia," said Arthur Sands, M.D., Ph.D., president and chief executive officer of Nurix. "We look forward to a very exciting year as we generate clinical data that can support further development of NX-2127, a first-in-class targeted protein degrader of BTK, a highly validated target for hematologic malignancies."

    Recent Business Highlights

    • Submitted first IND application for lead program NX-2127 and received clearance by the U.S. Food and Drug Administration (FDA). Nurix expects to dose the first patient in a Phase 1a/1b trial for NX-2127 in patients with relapsed or refractory B-cell malignancies in the first quarter of 2021 (expected timing of clinical trials here and throughout the press release are based on calendar year periods).



    • Expanded Sanofi collaboration: On January 7, 2021, Nurix announced that Sanofi exercised its option to increase the number of targets to a total of five, up from the original three targets in the strategic collaboration signed in December 2019. The option exercise triggered a one-time $22 million payment to Nurix, adding to the previously received $55 million upfront payment. As part of the multi-year collaboration, Nurix is using its proprietary drug discovery platform, DELigase™, that integrates its DNA-encoded libraries (DEL) and its portfolio of E3 ligases to create small molecules designed to induce degradation of specified drug targets. Sanofi will have exclusive rights and be responsible for clinical development and commercialization of drug candidates resulting from the work while Nurix will retain the option to co-develop and co-promote up to two products in the United States under certain conditions.



    • Presented Preclinical Data Highlighting Pipeline Programs: In December 2020, the Company presented IND-enabling data from its NX-2127 program at the American Society of Hematology (ASH) Annual Meeting, including data in non-human primates demonstrating rapid and sustained degradation of BTK with once daily oral dosing. In October 2020, at the Targeted Protein Degradation Summit, data were presented from the Company's NX-1607 program. NX-1607 is an inhibitor of Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) that is being developed for immuno-oncology indications. The data demonstrated both single agent anti-tumor activity of NX-1607 and combination anti-tumor activity with an anti-PD-1 antibody in animal models.



    • Completed Initial Public Offering (IPO) in July 2020 raising approximately $238.5 million in gross proceeds: On July 23, 2020, Nurix announced the pricing of its IPO of 11,000,000 shares of common stock, at a public offering price of $19.00 per share. In addition, the underwriters subsequently exercised their option to purchase 1,550,000 additional shares of common stock. The net proceeds to Nurix from the offering were approximately $218.1 million, after deducting underwriting discounts, commissions and offering expenses.



    • Strengthened Leadership Team with Key Appointments. In 2020, the Company added Michael Lotze, M.D., as chief cellular therapy officer and Robert Brown, M.D., as vice president of clinical development to help advance protein modulating drug candidates and cell therapy programs into the clinic. The Company also enhanced the financial team with the addition of Jason Kantor, Ph.D., as senior vice president, finance and investment strategy.

    Upcoming Program Highlights

    • NX-2127: The Company's lead drug candidate from its protein degradation portfolio, NX-2127, is an orally available degrader of Bruton's tyrosine kinase (BTK) with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies. The Company has an open IND and anticipates dosing the first patient in a Phase 1a/1b trial for NX-2127 in the first quarter of 2021.



    • NX-1607: The Company's lead drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally available inhibitor of CBL-B for immuno-oncology indications. The Company anticipates commencing a Phase 1 trial for NX-1607 in the second half of 2021.



    • NX-5948: The Company's second drug candidate from its protein degradation portfolio, NX-5948, is an orally available BTK degrader designed without IMiD activity for certain B-cell malignancies, autoimmune diseases and related diseases such as graft-versus-host disease. The Company anticipates commencing a Phase 1 trial for NX-5948 in the second half of 2021.



    • DeTIL-0255: The Company's lead candidate in its cellular therapy portfolio, DeTIL-0255, is a drug-enhanced adoptive cellular therapy. The Company anticipates commencing a Phase 1 trial for DeTIL-0255 in the second half of 2021.

    Fiscal Fourth Quarter and Full Year 2020 Financial Results

    Collaboration revenue for the three months and twelve months ended November 30, 2020 was $6.7 million and $17.8 million, respectively, compared with $1.9 million and $31.1 million for the three and twelve months ended November 30, 2019. The decrease in collaboration revenue for the full year was attributable to the termination of a collaboration agreement with Celgene Corporation in June 2019, which resulted in no revenue recognition in 2020, offset by revenue recognized related to the Company's collaboration agreements with Gilead Sciences, Inc. and Sanofi S.A. that were established in July and December 2019, respectively.

    Research and development expenses for the three months and twelve months ended November 30, 2020 were $20.4 million and $66.5 million, respectively, compared with $12.8 million and $45.0 million for the three and twelve months ended November 30, 2019. The increase was primarily related to increases in preclinical development activities and drug discovery research as well as increased expenses related to higher headcount.

    General and administrative expenses for the three months and twelve months ended November 30, 2020 were $6.3 million and $16.3 million, respectively, compared with $2.6 million and $8.3 million for the three and twelve months ended November 30, 2019. The increase was primarily related to higher headcount and increased legal and accounting expenses associated with becoming a public company.

    Net loss attributed to common stockholders for the three months and twelve months ended November 30, 2020 was $19.9 million or ($0.51) per share and $43.2 million or ($2.76) per share, respectively, compared with $13.5 million or ($3.55) per share and $21.7 million or ($6.59) per share, respectively, for the three and twelve months ended November 30, 2019.

    Cash, Cash Equivalents and Investments: As of November 30, 2020, the Company had cash, cash equivalents and investments of $372.0 million, compared with $38.2 million as of November 30, 2019.

    About Nurix Therapeutics, Inc.

    Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix's extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix's drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix's wholly owned pipeline includes targeted protein degraders of Bruton's tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurix.com.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding our future financial or business performance, conditions, plans, prospects, trends or strategies and other financial and business matters; our current and prospective product candidates; the timing of our planned IND submissions for our product candidates; the planned timing and conduct of our clinical trial programs for our product candidates, preclinical activities, research and development costs, current and prospective collaborations; the potential advantages of our DELigase™ platform and product candidates; the extent to which our scientific approach and DELigase™ platform may potentially address a broad range of diseases; the estimated size of the market for our product candidates; and the timing and success of our development and commercialization of our anticipated product candidates. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company, may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions regarding the future of the Company's business, future plans and strategies, its development plans, its preclinical results and other future conditions. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, performance or events and circumstances could differ materially from those expressed or implied in our forward-looking statements due to a variety of factors, including risks and uncertainties related to our ability to advance our product candidates, obtain regulatory approval of and ultimately commercialize our product candidates, the timing and results of preclinical and clinical trials, our ability to fund development activities and achieve development goals, the impact of the COVID-19 pandemic on our business, our ability to protect intellectual property and other risks and uncertainties described under the heading "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 16, 2021 and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein.

    Contacts: 
     Investors: Media:
     Jason Kantor, Ph.D.Elizabeth Wolffe, Ph.D.
     Nurix Therapeutics, Inc.Wheelhouse Life Science Advisors
     
       



    Nurix Therapeutics, Inc.       
    Condensed Consolidated Statements of Operations       
    (in thousands, except share and per share amounts)       
    (unaudited)       
            
     Three Months Ended November 30, Year Ended November 30,
     2020 2019 2020 2019
    Collaboration revenue$6,689  $1,862  $17,820  $31,115 
    Operating expenses:       
    Research and development 20,445   12,824   66,494   45,025 
    General and administrative 6,252   2,602   16,309   8,326 
    Total operating expenses 26,697   15,426   82,803   53,351 
    Loss from operations (20,008)  (13,564)  (64,983)  (22,236)
    Interest and other income, net 135   255   1,206   776 
    Loss before income taxes (19,873)  (13,309)  (63,777)  (21,460)
    (Benefit) provision for income taxes 41   210   (20,535)  239 
    Net loss$(19,914) $(13,519) $(43,242) $(21,699)
    Net loss per share attributable to common stockholders, basic and diluted$(0.51) $(3.55) $(2.76) $(6.59)
    Weighted-average number of shares outstanding, basic and diluted 38,702,486   3,812,210   15,673,424   3,292,514 
            



    Nurix Therapeutics, Inc.   
    Condensed Consolidated Balance Sheets   
    (in thousands)   
    (unaudited)   
        
     November 30,
     2020 2019
    Assets   
    Current assets:   
    Cash and cash equivalents$119,356  $34,816 
    Short-term investments 161,792   2,904 
    Contract assets 7,500    
    Income tax receivable 3,846    
    Prepaid expenses and other current assets 5,940   1,634 
    Total current assets 298,434   39,354 
    Long-term investments 90,890   506 
    Property and equipment, net 6,672   3,871 
    Restricted cash 170   170 
    Other assets 177   147 
    Total assets$396,343  $44,048 
    Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)   
    Current liabilities:   
    Accounts payable$3,412  $1,598 
    Accrued and other current liabilities 8,328   4,927 
    Deferred revenue, current 32,799   9,612 
    Total current liabilities 44,539   16,137 
    Deferred revenue, net of current portion 60,685   35,693 
    Other long-term liabilities 850   1,737 
    Total liabilities 106,074   53,567 
    Redeemable convertible preferred stock    48,195 
    Stockholders' equity (deficit):   
    Common stock 39   4 
    Additional paid-in-capital 393,841   2,740 
    Accumulated other comprehensive income (loss) 87   (2)
    Accumulated deficit (103,698)  (60,456)
    Total stockholders' equity (deficit) 290,269   (57,714)
    Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)$396,343  $44,048 
        


    Primary Logo

    View Full Article Hide Full Article
  2. SAN FRANCISCO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the expansion of its global strategic collaboration with Sanofi to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with challenging diseases in multiple therapeutic areas. Sanofi has exercised its option to expand the number of targets in the collaboration agreement from three to a total of five targets. With the expansion, Nurix receives a payment of $22 million, in addition to the previously received upfront payment of $55 million. Nurix is also eligible to receive up to approximately $2.5 billion in total…

    SAN FRANCISCO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the expansion of its global strategic collaboration with Sanofi to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with challenging diseases in multiple therapeutic areas. Sanofi has exercised its option to expand the number of targets in the collaboration agreement from three to a total of five targets. With the expansion, Nurix receives a payment of $22 million, in addition to the previously received upfront payment of $55 million. Nurix is also eligible to receive up to approximately $2.5 billion in total payments based on the successful completion of certain research, pre-clinical, clinical, regulatory and sales milestones.

    "Our collaboration with Sanofi has been very productive and the expansion of this agreement reflects the progress we have made and our collective drive to develop and commercialize drugs to treat challenging diseases," said Arthur T. Sands, M.D., Ph.D., Nurix's chief executive officer. "We look forward to a busy new year as we expand our collaboration on these exciting new programs with Sanofi and we continue to advance four of our wholly-owned programs into clinical trials."

    As part of the multi-year collaboration signed in December 2019, Nurix is using its proprietary drug discovery platform, DELigase™, that integrates its DNA-encoded libraries (DEL) and its portfolio of E3 ligases to create small molecules designed to induce degradation of specified drug targets. Sanofi will have exclusive rights and be responsible for clinical development and commercialization of drug candidates resulting from the work while Nurix will retain the option to co-develop and co-promote up to two products in the United States under certain conditions. Nurix will be eligible for royalties on annual net sales of any commercial products that may result from the collaboration, excluding sales in the United States of any products for which Nurix exercises its option to co-develop and co-promote, for which Nurix and Sanofi share U.S. profits and losses evenly, and Nurix will be eligible to receive royalties on ex-U.S. net sales on all optioned products. The collaboration excludes Nurix's wholly owned pipeline for which Nurix retains all rights.

    About Nurix Therapeutics, Inc.

    Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix's extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix's drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix's wholly owned pipeline comprises targeted protein degraders of Bruton's tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogeneB, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurix.com.

    Forward Looking Statements

    Any statements made in this press release relating to future business performance, conditions, plans, prospects, trends, or strategies and other business matters, including statements regarding our plans to develop targeted protein degradation drugs in collaboration with Sanofi, the receipt of potential future milestone and royalty payments, and our ability to advance multiple wholly owned drugs into clinical development, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company, may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions regarding the future of the Company's business, future plans and strategies, its development plans, its preclinical results and other future conditions. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, performance or events and circumstances could differ materially from those expressed or implied in our forward-looking statements due to a variety of factors, including the risks and uncertainties described under the heading "Risk Factors" in our Quarterly Report on Form 10-Q filed with the SEC on October 14, 2020 and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein.



    Contacts:

    Investors:Media:
    Jason Kantor, Ph.D.Elizabeth Wolffe, Ph.D.
    Nurix Therapeutics, Inc.Wheelhouse Life Science Advisors
      



     



    Primary Logo

    View Full Article Hide Full Article
  3. SAN FRANCISCO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M.D., Ph.D., Nurix's chief executive officer, will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 3:40 p.m. EST.

    The presentation will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. An archived copy of the webcast will be available on the Nurix website for approximately 30 days after the event.

    About Nurix Therapeutics, Inc.
    Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development…

    SAN FRANCISCO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M.D., Ph.D., Nurix's chief executive officer, will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 3:40 p.m. EST.

    The presentation will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. An archived copy of the webcast will be available on the Nurix website for approximately 30 days after the event.

    About Nurix Therapeutics, Inc.

    Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix's extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix's drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix's wholly owned pipeline comprises targeted protein degraders of Bruton's tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurix.com.

    Contacts:

    Investors:

    Jason Kantor, Ph.D.

    Nurix Therapeutics, Inc.

                        Media:

    Elizabeth Wolffe, Ph.D.

    Wheelhouse Life Science Advisors



       


    Primary Logo

    View Full Article Hide Full Article
  4. SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the presentation of key preclinical data from its lead program, NX-2127, for the potential treatment of B-cell malignancies, at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition. Supported by these data, Nurix plans to initiate a Phase 1 clinical trial of orally administered NX-2127 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) in the first half of 2021.

    "The data presented at ASH demonstrate the unique dual properties of NX-2127 which is designed to overcome treatment failures…

    SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the presentation of key preclinical data from its lead program, NX-2127, for the potential treatment of B-cell malignancies, at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition. Supported by these data, Nurix plans to initiate a Phase 1 clinical trial of orally administered NX-2127 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) in the first half of 2021.

    "The data presented at ASH demonstrate the unique dual properties of NX-2127 which is designed to overcome treatment failures including resistance to approved agents while simultaneously activating additional cancer-fighting immune cells," said Robert Brown, M.D., vice president of clinical development of Nurix. "We look forward to advancing our novel targeted protein dual degrader to the clinic for patients with B-cell malignancies who have failed to respond to currently available therapies."

    NX-2127 catalyzes proteasomal degradation of Bruton's tyrosine kinase (BTK), an enzyme involved in B-cell development, differentiation and signaling that is critical for proliferation and survival of lymphoma and leukemia cells in many B-cell malignancies, including NHL and CLL. Inhibitors of BTK, such as ibrutinib, are approved for treatment of B-cell cancers, however specific mutations can arise in the BTK protein that confer resistance to these agents, thereby reducing their efficacy. Degradation of BTK has the potential to overcome resistance in patients harboring such mutations in BTK. In addition, NX-2127 catalyzes degradation of a transcription factor involved in regulating T-cell function, resulting in T-cell activation in a similar fashion to immunomodulatory imide drugs (IMiD) that have demonstrated efficacy in some aggressive B-cell malignancies.

    The data presented at ASH demonstrate that NX-2127 catalyzes potent and selective degradation of both wild type and ibrutinib-resistant mutant BTK (BTKC481S) in lymphoma cell lines and inhibits their growth. In addition, NX-2127 treatment of normal human T-cells results in their activation with similar potency to commercially available IMiDs, pomalidomide and lenalidomide, as measured by degradation of the transcription factor Aiolos and production of IL-2. Notably, orally administered NX-2127 results in potent anti-tumor effects in mouse xenograft models and rapid and near complete BTK degradation in preclinical testing in non-human primates with once-daily dosing.

    About Nurix Therapeutics, Inc.

    Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix's extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix's drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix's wholly owned pipeline comprises targeted protein degraders of Bruton's tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurix.com.

    Forward Looking Statement

    Any statements made in this press release relating to future business performance, conditions, plans, prospects, trends, or strategies and other business matters, including statements regarding our plans to file an IND and initiate clinical trials to develop NX-2127 for the treatment of B-cell malignancies, our ability to advance multiple wholly owned drugs into clinical development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions regarding the future of the Company's business, future plans and strategies, its development plans, its preclinical results and other future conditions. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, performance or events and circumstances could differ materially from those expressed or implied in our forward-looking statements due to a variety of factors, including the risks and uncertainties described under the heading "Risk Factors" in our final prospectus pursuant to Rule 424(b)(4) filed with the Securities and Exchange Commission (SEC) on July 24, 2020, our Quarterly Report on Form 10-Q filed with the SEC on October 14, 2020 and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein.

    Contacts:

    Investors:Media:
    Jason Kantor, Ph.D.Elizabeth Wolffe, Ph.D.
    Nurix Therapeutics, Inc.Wheelhouse Life Science Advisors


    Primary Logo

    View Full Article Hide Full Article
  5. SAN FRANCISCO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will be presenting at the following healthcare investor conferences:

    Stifel 2020 Virtual Healthcare Conference, November 16-18, 2020,
    Presenters: Arthur Sands, M.D., Ph.D., CEO and Hans Van Houte, CFO
    Presentation type: Fireside chat
    Presentation date: Tuesday, November 17, 2020 Time: 3:20 p.m. – 3:50 p.m. EST.
    The live presentation can be accessed via a link on the Events and Presentations page of the Nurix Therapeutics website.

    Piper Sandler 32nd Annual Virtual Healthcare Conference, December 1-3, 2020
    Presenter: Arthur Sands, M.D., Ph.D., CEO
    Presentation

    SAN FRANCISCO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will be presenting at the following healthcare investor conferences:

    Stifel 2020 Virtual Healthcare Conference, November 16-18, 2020,

    Presenters: Arthur Sands, M.D., Ph.D., CEO and Hans Van Houte, CFO

    Presentation type: Fireside chat

    Presentation date: Tuesday, November 17, 2020 Time: 3:20 p.m. – 3:50 p.m. EST.

    The live presentation can be accessed via a link on the Events and Presentations page of the Nurix Therapeutics website.

    Piper Sandler 32nd Annual Virtual Healthcare Conference, December 1-3, 2020

    Presenter: Arthur Sands, M.D., Ph.D., CEO

    Presentation type: Fireside chat

    A recording of the presentation will be available on the Events and Presentations page of the Nurix Therapeutics website from 10:00 a.m. EST on November 23, 2020.

    The presentations will be archived for 30 days and available on the  Events and Presentations page of the Nurix Therapeutics website.

    About Nurix Therapeutics, Inc.

    Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix's extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix's drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix's wholly owned pipeline comprises targeted protein degraders of Bruton's tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurix.com.

    Contacts:

    Investors:Media:
    Jason Kantor, Ph.D.Elizabeth Wolffe, Ph.D.
    Nurix Therapeutics, Inc.Wheelhouse Life Science Advisors

    Primary Logo

    View Full Article Hide Full Article
View All Nurix Therapeutics Inc. News